{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:25:26Z","timestamp":1723163126113},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,8]]},"DOI":"10.7759\/cureus.66425","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T10:42:52Z","timestamp":1723113772000},"source":"Crossref","is-referenced-by-count":0,"title":["Pembrolizumab-Related Sclerosing Cholangitis in a Patient With High Microsatellite Instability Gastric Cancer: A Case Report"],"prefix":"10.7759","author":[{"given":"Shusaku","family":"Honma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanae","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian YY","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al.. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021, 398:27-40. 10.1016\/S0140-6736(21)00797-2","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Kang YK","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH, et al.. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022, 23:234-47. 10.1016\/s1470-2045(21)00692-6","journal-title":"Lancet Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the Phase II KEYNOTE-158 study","volume":"38","author":"Marabelle A","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA, et al.. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the Phase II KEYNOTE-158 study. J Clin Oncol. 2020, 38:1-10. 10.1200\/JCO.19.02105","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian SL","year":"2015","unstructured":"Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015, 27:450-61. 10.1016\/j.ccell.2015.03.001","journal-title":"Cancer Cell"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.10663","article-title":"Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer","volume":"105","author":"Polom K","year":"2018","unstructured":"Polom K, Marano L, Marrelli D, et al.. Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer. Br J Surg. 2018, 105:159-67. 10.1002\/bjs.10663","journal-title":"Br J Surg"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)31257-1","article-title":"Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial","volume":"392","author":"Shitara K","year":"2018","unstructured":"Shitara K, \u00d6zg\u00fcro\u011flu M, Bang YJ, et al.. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018, 392:123-33. 10.1016\/s0140-6736(18)31257-1","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000005501","article-title":"Survival of locally advanced MSI-high gastric cancer patients treated with perioperative chemotherapy: a retrospective cohort study","volume":"277","author":"Vos EL","year":"2023","unstructured":"Vos EL, Maron SB, Krell RW, et al.. Survival of locally advanced MSI-high gastric cancer patients treated with perioperative chemotherapy: a retrospective cohort study. Ann Surg. 2023, 277:798-805. 10.1097\/SLA.0000000000005501","journal-title":"Ann Surg"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-022-02661-8","article-title":"Conversion surgery for microsatellite instability-high gastric cancer with a complete pathological response to pembrolizumab: a case report","volume":"20","author":"Hidaka Y","year":"2022","unstructured":"Hidaka Y, Arigami T, Osako Y, et al.. Conversion surgery for microsatellite instability-high gastric cancer with a complete pathological response to pembrolizumab: a case report. World J Surg Oncol. 2022, 20:193. 10.1186\/s12957-022-02661-8","journal-title":"World J Surg Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-022-00581-8","article-title":"Eldest gastric cancer patient with high microsatellite instability responding to pembrolizumab","volume":"12","author":"Wakasugi A","year":"2023","unstructured":"Wakasugi A, Sasaki A, Okamoto R, Motomura Y. Eldest gastric cancer patient with high microsatellite instability responding to pembrolizumab. Int Cancer Conf J. 2023, 12:59-62. 10.1007\/s13691-022-00581-8","journal-title":"Int Cancer Conf J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of immunotherapy for the practitioner","volume":"33","author":"Weber JS","year":"2015","unstructured":"Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J Clin Oncol. 2015, 33:2092-9. 10.1200\/JCO.2014.60.0379","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-020-01677-9","article-title":"Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies","volume":"55","author":"Mizuno K","year":"2020","unstructured":"Mizuno K, Ito T, Ishigami M, et al.. Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies. J Gastroenterol. 2020, 55:653-61. 10.1007\/s00535-020-01677-9","journal-title":"J Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw649","article-title":"Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury","volume":"28","author":"Gelsomino F","year":"2017","unstructured":"Gelsomino F, Vitale G, D'Errico A, Bertuzzi C, Andreone P, Ardizzoni A. Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. Ann Oncol. 2017, 28:671-2. 10.1093\/annonc\/mdw649","journal-title":"Ann Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-017-0453-0","article-title":"Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer","volume":"35","author":"Kawakami H","year":"2017","unstructured":"Kawakami H, Tanizaki J, Tanaka K, et al.. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs. 2017, 35:529-36. 10.1007\/s10637-017-0453-0","journal-title":"Invest New Drugs"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i3.353","article-title":"Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review","volume":"26","author":"Onoyama T","year":"2020","unstructured":"Onoyama T, Takeda Y, Yamashita T, et al.. Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review. World J Gastroenterol. 2020, 26:353-65. 10.3748\/wjg.v26.i3.353","journal-title":"World J Gastroenterol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors","volume":"13","author":"Chennamadhavuni A","year":"2022","unstructured":"Chennamadhavuni A, Abushahin L, Jin N, Presley CJ, Manne A. Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors. Front Immunol. 2022, 13:779691. 10.3389\/fimmu.2022.779691","journal-title":"Front Immunol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.585311","article-title":"Biomarkers of checkpoint inhibitor induced immune-related adverse events-a comprehensive review","volume":"10","author":"Hommes JW","year":"2020","unstructured":"Hommes JW, Verheijden RJ, Suijkerbuijk KP, Hamann D. Biomarkers of checkpoint inhibitor induced immune-related adverse events-a comprehensive review. Front Oncol. 2020, 10:585311. 10.3389\/fonc.2020.585311","journal-title":"Front Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S247554","article-title":"Multiple immune-related adverse events and anti-tumor efficacy: real-world data on various solid tumors","volume":"12","author":"Shimozaki K","year":"2020","unstructured":"Shimozaki K, Sukawa Y, Beppu N, et al.. Multiple immune-related adverse events and anti-tumor efficacy: real-world data on various solid tumors. Cancer Manag Res. 2020, 12:4585-93. 10.2147\/CMAR.S247554","journal-title":"Cancer Manag Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.12281","article-title":"Prognosis of immune-related adverse events in patients with advanced gastric cancer treated with nivolumab or pembrolizumab: a multicenter retrospective analysis","volume":"35","author":"Ando T","year":"2021","unstructured":"Ando T, Ueda A, Ogawa K, et al.. Prognosis of immune-related adverse events in patients with advanced gastric cancer treated with nivolumab or pembrolizumab: a multicenter retrospective analysis. In Vivo. 2021, 35:475-82. 10.21873\/invivo.12281","journal-title":"In Vivo"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider BJ","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021, 39:4073-126. 10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille C","year":"2020","unstructured":"Dolladille C, Ederhy S, Sassier M, et al.. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol. 2020, 6:865-71. 10.1001\/jamaoncol.2020.0726","journal-title":"JAMA Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/278695-pembrolizumab-related-sclerosing-cholangitis-in-a-patient-with-high-microsatellite-instability-gastric-cancer-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T10:42:56Z","timestamp":1723113776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/278695-pembrolizumab-related-sclerosing-cholangitis-in-a-patient-with-high-microsatellite-instability-gastric-cancer-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.66425","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,8]]}}}